|M19970||Aficamten (CK-274)||Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractile force in vitro and in vivo with an IC50 of 1.4 μM.|
|M13758||MLCK inhibitor peptide 18||MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.|
|M13409||ATM-3507 trihydrochloride||ATM-3507 is a potent inhibitor of Tropomyosin with an IC50 value of 3.83-6.84μM in human melanoma cell lines.|
|M10262||Mavacamten (MYK-461)||Mavacamten, also known as SAR-439152 and MYK-461, is the first (first-class) orally bioavailable allosteric and reversible selective inhibitor of Cardiac Myosin. The IC50 of bovine heart and human heart was 490 nM and 711 nM, respectively.|
|M9636||Blebbistain||(±)-Blebbistatin (BLEB) is a small cell permeable selective myosin II inhibitor which potently relaxed normal detrusor smooth muscle.|
|M7624||2,3-Butanedione monoxime||2,3-Butanedione Monoxime (BDM) is a myosin ATPASE inhibitor. 2,3-Butanedione Monoxime is a skeletal and cardiac muscle contraction inhibitor. 2,3-Butanedione monoxime induces sarcoplasmic reticulum Ca2+ release.|
|M2459||Blebbistatin||Blebbistatin is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly. *The compound is unstable in solutions, freshly prepared is recommended|
|M2004||Omecamtiv mecarbil||Omecamtiv mecarbil (CK-1827452), a specific cardiac myosin agonist, is a clinical compound used in left ventricular systolic heart failure.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.